SPDR S&P Telecom (XTL) 57.41 $XTL
XTL Biopharmaceuticals Reports Financial and Operational Results for the Full Year Ended 2013
PR Newswire - Wed Apr 02, 3:41PM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the year ended December 31, 2013.
XTL Biopharmaceuticals Retains Expert Consultants in Rheumatology for Phase II Lupus Trial
PR Newswire - Tue Mar 25, 7:00AM CDT
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"

, a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of Daniel J. Wallace, MD and Murray Urowitz, MD, two experts in rheumatology, as consultants for the planned Phase II trial for the Company's hCDR1 compound for the treatment of Lupus (Systemic Lupus Erythematosus - SLE) patients.
The Comprehensive Guide to Telecom ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 10:47AM CST
Telecom industry is expected to maintain its upward momentum going forward.